Low Discontinuation Rates at 90 Days and 192 Weeks

PREZISTA^® /r: Tolerability Proven Over Time

Low discontinuation due to ADRs* with Once-Daily PREZISTA^®/r in the first 90 days and through 192 weeks^{1,
2}

Low discontinuation due to ADRs* with Once-Daily PREZISTA®/r in the first 90 days and through 192 weeks

^* Excluding laboratory abnormalities as ADRs.

ADRs=adverse drug reactions; TDF/FTC=tenofovir disoproxil fumarate/emtricitabine.

Kaletra (lopinavir/ritonavir) is a registered trademark of AbbVie Inc.

Print Page

Your use of the information on this site is subject to the terms of our Legal Notice. Please see our Privacy Policy. This site is published by Janssen Therapeutics, Division of Janssen Products, LP, which is solely responsible for its contents.

The material on this site is intended only as informational or as an educational aid and it is not intended to be taken as medical advice. The ultimate responsibility for patient care resides with a healthcare professional.

This information is intended for the use of our customers, patients, and healthcare professionals in the United States only. Laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States.

Capitalized product names are trademarks of Janssen Therapeutics, Division of Janssen Products, LP.

This site was last updated on: 06/28/19 at 09:11 pm EST

Low discontinuation due to ADRs* with Once-Daily PREZISTA®/r in the first 90 days and through 192 weeks1, 2

Low discontinuation due to ADRs* with Once-Daily PREZISTA^®/r in the first 90 days and through 192 weeks^{1,
2}